

ASX/Media Release (Code: PRR)
17 January 2012

JAPANESE PATENT GRANTED FOR CRIPTO-1 ANTIBODY

Australian cancer treatment development company Prima BioMed Ltd ("Prima") (ASX: PRR) is pleased to announce that it has received Notification of Grant by the Japanese Patent Office for its antibody to cancer antigen Cripto-1.

Patent number 4854912 is titled, **Antibodies against Cancer** and expires in March 2022. The patent has also been granted in Australia, New Zealand, China, South Korea and the USA.

The granted patent claims protect the use of an antibody directed to the cancer antigen Cripto-1. Cripto -1 is a protein found in high levels on the surface of many different kinds of cancer cells and is also found to circulate in the blood stream of cancer patients. The antibody works by binding to the Cripto-1 molecule and interfering with cell signalling, resulting in the death of the cancer cell. The antibody may additionally be coupled to cytotoxic drugs to deliver a more lethal combination of drug and cell signal to cancer cells.

ENDS

For further information please contact:

Martin Rogers
Chief Executive Officer
Prima BioMed
Ph: +61 2 9276 1242
E: martin.rogers@primabiomed.com.au
Website: www.primabiomed.com.au

Mr James Moses
Investor and Media Relations
Mandate Corporate
Ph: +61 (0) 420 991 574
E: james@mandatecorporate.com.au

About CVac™ Ovarian Cancer Treatment

CVac™ is Prima BioMed's core product. It is a vaccine therapy treatment for ovarian cancer sufferers that are administered post-surgery and post-chemotherapy to delay the relapse and control the metastases of the cancer. There is a large un-met medical need for new treatments for ovarian cancer which has a very high morbidity rate, and there are currently no maintenance-based therapy products commercially available.

The Company has commenced its Phase IIb Trial for CVac™ with the US FDA and plans to commence a Phase III Clinical Trial for CVac™ in Europe and the US this year. The Phase IIb and Phase III Trials aim to further confirm the ability of CVac™ to reduce the instance of relapse in ovarian cancer patients, control the metastases of the cancer and increase the life expectancy of patients.

Prima's ultimate goal is to commercialise CVac™ into the multi-billion dollar global pharmacy oncology market. The global market for ovarian cancer therapeutics was valued at US\$2.1b in 2007 and was estimated to have grown to US\$3.6b by 2010.

Regulatory approval and commercialization of CVac™ is the core focus for Prima.

About Prima BioMed

Prima BioMed is an ASX listed Australian health care company. The Company is focused on technologies in the fields of cancer immunotherapy and immunology.

Prima's lead product is CVac™ ovarian cancer therapy treatment. It has completed two successful clinical trials and is progressing toward eventual commercialization in the United States, Australia, Europe, and globally.

The Company's broader, long term goal is to develop commercial cancer treatment technologies and programs for global markets.